Literature DB >> 23775048

Effects of controlled discontinuation of long-term used antipsychotics on weight and metabolic parameters in individuals with intellectual disability.

Gerda de Kuijper1, Hans Mulder, Heleen Evenhuis, Frank Visser, Pieter J Hoekstra.   

Abstract

Antipsychotics are frequently prescribed agents in individuals with intellectual disability, often for behavioral symptoms. Efficacy of antipsychotics for this is ambiguous, so discontinuation should be considered. Weight gain and metabolic dysregulation are well-known adverse effects of antipsychotics which increase the risk of the metabolic syndrome. We performed a discontinuation study in 99 adults with intellectual disability, living in residential facilities who used antipsychotics for behavioral symptoms for more than 1 year. The aim of the present study was to investigate the effects of discontinuation of long-term used antipsychotics on weight, body mass index (BMI), and parameters of the metabolic syndrome and to investigate the influence of genetic polymorphisms and medication factors on these outcomes. Discontinuation of antipsychotics led to a mean decrease of 4 cm waist circumference, of 3.5 kg weight, 1.4 kg/m2 BMI, and 7.1 mm Hg systolic blood pressure. In those participants who had not completely discontinued use of antipsychotics we found a decrease in weight and BMI and an increase in fasting glucose. The presence of the C-allele of serotonin 5-hydroxytryptamine receptor polymorphism rs141334 was associated with higher waist circumference and higher plasma levels of triglycerides and lower levels of high-density lipoprotein. Achievement of complete discontinuation predicted a larger decrease in waist circumference and BMI. In conclusion, results of the study show the beneficial effects of discontinuation of long-term used antipsychotics on metabolic outcomes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23775048     DOI: 10.1097/JCP.0b013e3182905d6a

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  6 in total

1.  Primary care of adults with intellectual and developmental disabilities: 2018 Canadian consensus guidelines.

Authors:  William F Sullivan; Heidi Diepstra; John Heng; Shara Ally; Elspeth Bradley; Ian Casson; Brian Hennen; Maureen Kelly; Marika Korossy; Karen McNeil; Dara Abells; Khush Amaria; Kerry Boyd; Meg Gemmill; Elizabeth Grier; Natalie Kennie-Kaulbach; Mackenzie Ketchell; Jessica Ladouceur; Amanda Lepp; Yona Lunsky; Shirley McMillan; Ullanda Niel; Samantha Sacks; Sarah Shea; Katherine Stringer; Kyle Sue; Sandra Witherbee
Journal:  Can Fam Physician       Date:  2018-04       Impact factor: 3.275

2. 

Authors:  William F Sullivan; Heidi Diepstra; John Heng; Shara Ally; Elspeth Bradley; Ian Casson; Brian Hennen; Maureen Kelly; Marika Korossy; Karen McNeil; Dara Abells; Khush Amaria; Kerry Boyd; Meg Gemmill; Elizabeth Grier; Natalie Kennie-Kaulbach; Mackenzie Ketchell; Jessica Ladouceur; Amanda Lepp; Yona Lunsky; Shirley McMillan; Ullanda Niel; Samantha Sacks; Sarah Shea; Katherine Stringer; Kyle Sue; Sandra Witherbee
Journal:  Can Fam Physician       Date:  2018-04       Impact factor: 3.275

3.  Characteristics of Children Prescribed Antipsychotics: Analysis of Routinely Collected Data.

Authors:  Sinead Brophy; Jonathan Kennedy; Fabiola Fernandez-Gutierrez; Ann John; Robert Potter; Christine Linehan; Michael Kerr
Journal:  J Child Adolesc Psychopharmacol       Date:  2018-02-27       Impact factor: 2.576

4.  Recognition and treatment of mood dysregulation in adults with intellectual disability.

Authors:  Jason Noel
Journal:  Ment Health Clin       Date:  2018-11-01

5.  Reversibility of Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis.

Authors:  Helene Speyer; Casper Westergaard; Nikolai Albert; Mette Karlsen; Anne Emilie Stürup; Merete Nordentoft; Jesper Krogh
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-28       Impact factor: 5.555

6.  Management of psychotropic medications in adults with intellectual disability: a scoping review.

Authors:  Ashley Costello; Eithne Hudson; Susan Morrissey; Drona Sharma; Dervla Kelly; Owen Doody
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.